Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Trial details
- Registry ID
- NCT04467840
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as ABC294640; Yeliva
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840 | RedHill Biopharma Limited | Phase 2, Phase 3 | Completed | 2021-07-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |